Repression of WT1-Mediated LEF1 Transcription by Mangiferin Governs β-Catenin-Independent Wnt Signalling Inactivation in Hepatocellular Carcinoma

Background/Aims: The development of hepatocellular carcinoma (HCC) is a complex process which involves deregulation of multiple signalling pathways. The hyper-activation of Wnt signalling promotes sustained expansion, invasion, and neovascularization of HCC. Mangiferin, a natural small molecule present in Mangifera indica L. has been shown to inactivate β-catenin, which is an indispensable regulator in Wnt pathway. Our study aimed to determine whether mangiferin has any inhibitory effect on HCC and examine how it modulates Wnt signalling. Methods: The tumour inhibitory effect of mangiferin was examined by in vitro cellular models and an in vivo orthotopic HCC implantation model. The genes responsible for mangiferin-mediated anti-HCC were delineated by polymerase chain reaction (PCR) microarray. The expression of target genes was further determined by quantitative PCR and immuno-blotting assays. The binding capacity of Wilms’ tumour 1 (WT1) to the lymphoid enhancer-binding factor 1 (LEF1) promoter was confirmed by chromatin immunoprecipitation-qPCR. Results: Oral administration of mangiferin inhibited orthotopic tumour growth. Cellular investigations confirmed the dose-dependent inhibition of mangiferin on HCC expansion and invasion. PCR array combined with Gene Ontology analysis revealed that the Wnt pathway was the predominant target of mangiferin and LEF1 was the most reduced gene in the Wnt pathway. Overexpression of LEF1 diminished repression of Wnt signalling and reduced proliferation activity in mangiferin-treated HCC cells. The mangiferin-mediated down-regulation of LEF1 was independent of β-catenin but associated with WT1 protein. WT1 knock-in in HCC cells further enhanced LEF1 expression. Chromatin immunoprecipitation assays revealed that the mangiferin induced repression of LEF1 was associated with decreased occupancy of WT1 on the LEF1 promoter. Conclusion: Our study identifies a novel mechanism of hepatocellular carcinoma inhibition through β-catenin-independent Wnt signalling, which is regulated by WT1-associated LEF1 repression. The study also highlights mangiferin as a promising Wnt inhibitor for HCC treatment.

[1]  You-hong Jiang,et al.  TLR4 Influences Hepatitis B Virus Related Hepatocellular Carcinoma by Regulating the Wnt/β-Catenin Pathway , 2017, Cellular Physiology and Biochemistry.

[2]  Alan D. Lopez,et al.  Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study , 2017, JAMA oncology.

[3]  Zhuo-wei Hu,et al.  The regulation of β-catenin activity and function in cancer: therapeutic opportunities , 2017, Oncotarget.

[4]  G. Santoni,et al.  Mangiferin blocks proliferation and induces apoptosis of breast cancer cells via suppression of the mevalonate pathway and by proteasome inhibition. , 2016, Food & function.

[5]  M. Daglia,et al.  The potential role of mangiferin in cancer treatment through its immunomodulatory, anti‐angiogenic, apoptopic, and gene regulatory effects , 2016, BioFactors.

[6]  Alyssa Fernandez,et al.  Mangiferin and Cancer: Mechanisms of Action , 2016, Nutrients.

[7]  M. Yuen,et al.  IRE1α inhibition by natural compound genipin on tumour associated macrophages reduces growth of hepatocellular carcinoma , 2016, Oncotarget.

[8]  J. Waisberg,et al.  Wnt-/-β-catenin pathway signaling in human hepatocellular carcinoma. , 2015, World journal of hepatology.

[9]  Junjian Zhang,et al.  Mangiferin regulates proliferation and apoptosis in glioma cells by induction of microRNA-15b and inhibition of MMP-9 expression. , 2015, Oncology reports.

[10]  J. Yang,et al.  Mangiferin induces cell cycle arrest at G2/M phase through ATR-Chk1 pathway in HL-60 leukemia cells. , 2015, Genetics and molecular research : GMR.

[11]  Y. Xiong,et al.  WT1 recruits TET2 to regulate its target gene expression and suppress leukemia cell proliferation. , 2015, Molecular cell.

[12]  Yue Ma,et al.  LEF1 regulates glioblastoma cell proliferation, migration, invasion, and cancer stem-like cell self-renewal , 2014, Tumor Biology.

[13]  E. Toska,et al.  WT1 regulates the development of the posterior taste field , 2014, Development.

[14]  Miran Kim,et al.  Wnt signaling and hepatocarcinogenesis: molecular targets for the development of innovative anticancer drugs. , 2013, Journal of hepatology.

[15]  Wei Cheng,et al.  Mangiferin exerts antitumor activity in breast cancer cells by regulating matrix metalloproteinases, epithelial to mesenchymal transition, and β-catenin signaling pathway. , 2013, Toxicology and applied pharmacology.

[16]  Joshua Brody,et al.  β-Catenin-Independent Activation of TCF1/LEF1 in Human Hematopoietic Tumor Cells through Interaction with ATF2 Transcription Factors , 2013, PLoS genetics.

[17]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[18]  S. Safe,et al.  MicroRNA-26b Represses Colon Cancer Cell Proliferation by Inhibiting Lymphoid Enhancer Factor 1 Expression , 2013, Molecular Cancer Therapeutics.

[19]  Motoko Sasaki,et al.  Association of Interleukin-28B Genotype and Hepatocellular Carcinoma Recurrence in Patients with Chronic Hepatitis C , 2013, Clinical Cancer Research.

[20]  Xi He,et al.  Frizzled and LRP5/6 receptors for Wnt/β-catenin signaling. , 2012, Cold Spring Harbor perspectives in biology.

[21]  M. Waterman,et al.  TCF/LEFs and Wnt signaling in the nucleus. , 2012, Cold Spring Harbor perspectives in biology.

[22]  Y. Jeng,et al.  Hepatocyte growth factor activates Wnt pathway by transcriptional activation of LEF1 to facilitate tumor invasion. , 2012, Carcinogenesis.

[23]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[24]  D. Rimm,et al.  β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. , 2011, Cancer cell.

[25]  L. Trusolino,et al.  Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils , 2011, EMBO molecular medicine.

[26]  H. Koga,et al.  Identification of T-cell factor-4 isoforms that contribute to the malignant phenotype of hepatocellular carcinoma cells. , 2011, Experimental cell research.

[27]  V. Huff,et al.  Wilms' tumours: about tumour suppressor genes, an oncogene and a chameleon gene , 2011, Nature Reviews Cancer.

[28]  Xi He,et al.  Wnt/beta-catenin signaling: components, mechanisms, and diseases. , 2009, Developmental cell.

[29]  Marc Ladanyi,et al.  WNT/TCF Signaling through LEF1 and HOXB9 Mediates Lung Adenocarcinoma Metastasis , 2009, Cell.

[30]  Jared M Flatow,et al.  An integrated genome screen identifies the Wnt signaling pathway as a major target of WT1 , 2009, Proceedings of the National Academy of Sciences.

[31]  S. Altekruse,et al.  Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  X. Wang,et al.  EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. , 2009, Gastroenterology.

[33]  J. Prieto,et al.  Wilms' tumor 1 gene expression in hepatocellular carcinoma promotes cell dedifferentiation and resistance to chemotherapy. , 2009, Cancer research.

[34]  Qian He,et al.  Major Mango Polyphenols and Their Potential Significance to Human Health. , 2008, Comprehensive reviews in food science and food safety.

[35]  F. Trevisani,et al.  Recent advances in the natural history of hepatocellular carcinoma. , 2008, Carcinogenesis.

[36]  E. Yu,et al.  Functional interaction between Wnt3 and Frizzled-7 leads to activation of the Wnt/beta-catenin signaling pathway in hepatocellular carcinoma cells. , 2008, Journal of hepatology.

[37]  M. Konstadoulakis,et al.  Strategies for the management of hepatocellular carcinoma , 2007, Nature Clinical Practice Oncology.

[38]  L. Attisano,et al.  Association of Smads with lymphoid enhancer binding factor 1/T cell-specific factor mediates cooperative signaling by the transforming growth factor-beta and wnt pathways. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Rudolf Grosschedl,et al.  Modulation of Transcriptional Regulation by LEF-1 in Response to Wnt-1 Signaling and Association with β-Catenin , 1998, Molecular and Cellular Biology.

[40]  Peng Li,et al.  Mangiferin inhibition of proliferation and induction of apoptosis in human prostate cancer cells is correlated with downregulation of B-cell lymphoma-2 and upregulation of microRNA-182. , 2016, Oncology letters.

[41]  Yu Luo,et al.  Mangiferin induces apoptosis by regulating Bcl-2 and Bax expression in the CNE2 nasopharyngeal carcinoma cell line. , 2014, Asian Pacific journal of cancer prevention : APJCP.

[42]  S. Fan,et al.  beta-Catenin mutation and overexpression in hepatocellular carcinoma: clinicopathologic and prognostic significance. , 2001, Cancer.